A Multinational, Multicenter, Randomized, Parallel Group, Double Blind, Placebo Controlled Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate 20mg/0.5mL New Formulation Administered Daily by Subcutaneous Injection

Trial Profile

A Multinational, Multicenter, Randomized, Parallel Group, Double Blind, Placebo Controlled Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate 20mg/0.5mL New Formulation Administered Daily by Subcutaneous Injection

Discontinued
Phase of Trial: Phase III

Latest Information Update: 30 May 2014

At a glance

  • Drugs Glatiramer acetate (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms GLOW
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 08 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 26 May 2012 Additional trial locations added as reported by European Clinical Trials Database.
    • 26 May 2012 New source identified and integrated (European Clinical Trials Database, EudraCT2011-005550-57).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top